Skip to Content


Intent To Grant an Exclusive License of a U.S. Government-Owned Invention

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Department of the Army, DoD.




In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i) and 37 CFR 404.7(b)(1)(i), announcement is made of the intent to grant an exclusive, revocable license to the invention claimed in U.S. Patent No. 6,316,197, entitled “Method of Diagnosing of Exposure to Toxic Agents by Measuring Distinct Pattern in the Levels of Expression of Specific Genes,” issued on November 13, 2001, and foreign rights to Cascade Biotherapeutics, Inc., with its principal place of business at 4938 Hampden Lane #319, Bethesda, Maryland 20814-2914.


Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, MD 21702-5012.

Start Further Info


For licensing issues, Dr. Paul Mele, Office of Research & Technology Applications, (301) 619-6664. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808; both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information


Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES).

Start Signature

Brenda S. Bowen,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 2013-00226 Filed 1-8-13; 8:45 am]